Biotech giant Moderna will submit data on a new vaccine for respiratory syncytial virus (RSV) to the Therapeutic Goods Administration this year in hopes of getting a product approved for older Australians as soon as 2024.

The $US73.2 billion ($104.8 billion) global vaccine maker revealed on Wednesday morning that a phase 3 trial for its vaccine against the respiratory disease showed it was 83.7 per cent effective in preventing at least two symptoms of the virus in adults aged over 60.

RSV is a seasonal virus that can cause coughing, congestion and a sore throat, but can also lead to serious illness in infants and older adults. It was first identified in the mid-1950s, and researchers have been working on a vaccine for the product ever since.

Cases of RSV climbed during the winter months last year, with the virus responsible for more paediatric admissions to Victorian hospitals than COVID-19 or the flu last July. 

Moderna’s chief medical officer, Dr Paul Burton, said the company was now finalising its data on the vaccine for older adults to submit the product for approval to regulators.

“We would hope that we would have approvals really by the end of 2023 into early ’24, for that northern hemisphere season, and then obviously, be ready for the subsequent southern hemisphere winter in 2024,” he said.

The company is also running trials of an RSV product for infants, toddlers and pregnant women. Burton said the strength of the data from the older adults trial is a good sign for the possible use of the vaccine by other groups.

“I would be cautiously optimistic that we’ll see equally good, strong effectiveness and efficacy results in those other groups of people,” he said.

The vaccine eventually could be made in Australia at Moderna’s mRNA vaccine manufacturing plant in Melbourne, which the company is building with a view to providing a range of respiratory disease products beyond its current COVID-19 vaccine.